Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors

Description

This study will enroll patients initiating Bruton Tyrosine Kinase (BTK) inhibitors without history of documented arrhythmia while on therapy using the Medtronic LINQ-2 insertable cardiac monitor (ILR). The incidence of new onset atrial fibrillation (AF) and other arrhythmia will be determined. Actions taken in response to device detected arrhythmia will be recorded.

Conditions

Atrial Fibrillation, Supraventricular Arrhythmia, Ventricular Arrhythmias and Cardiac Arrest, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Talk to us

Study Overview

On this page

Study Details

Study overview

This study will enroll patients initiating Bruton Tyrosine Kinase (BTK) inhibitors without history of documented arrhythmia while on therapy using the Medtronic LINQ-2 insertable cardiac monitor (ILR). The incidence of new onset atrial fibrillation (AF) and other arrhythmia will be determined. Actions taken in response to device detected arrhythmia will be recorded.

Implanted Loop Recorders (ILR) for the Detection and Management of Arrhythmia in Patients Treated With Bruton Tyrosine Kinase (BTK) Inhibitors

Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors

Condition
Atrial Fibrillation
Intervention / Treatment

-

Contacts and Locations

New Hyde Park

Northwell (Northshore University/Long Island Jewish Hospitals), New Hyde Park, New York, United States, 11040

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * \>18yo
  • * Willing to sign and date consent form,
  • * Willing to be remotely monitored
  • * Initiating BTK inhibitor for approved condition (i.e. CLL, Waldenstrom's, etc)
  • * Willing to have Medtronic cardiac monitor inserted to allow at minimum 24 hours continuous monitoring prior to initiating BTK inhibitor
  • * Documented AF/VA in past 12 months
  • * Cerebral Vascular Accident (CVA) or Transient Ischemic Attack (TIA) in past year
  • * Has current implanted pulse generator, defibrillator, pacemaker, or resynchronization device
  • * heart surgery within past 90 days
  • * Myocardial Infarction within past 90 days
  • * Patient is taking an anti-arrhythmic or anticoagulant
  • * has concomitant condition that precludes safe participation in study (substance abuse, etc)
  • * Enrollment in separate study that could confound results of this study

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Northwell Health,

Robert S Copeland-Halperin, MD, PRINCIPAL_INVESTIGATOR, Northwell Health

Haisam Ismail, MD, PRINCIPAL_INVESTIGATOR, Northwell Health

Study Record Dates

2030-12-01